Novel anticonvulsant drugs
Tóm tắt
Từ khóa
Tài liệu tham khảo
Adler, 1997, Treatment of restless legs syndrome with gabapentin, Clin Neuropharmacol, 20, 148, 10.1097/00002826-199704000-00006
Averbuch-Heller, 1997, A double-blind controlled study of gabapentin and baclofen as treatment for acquired nystagmus, Ann Neurol, 41, 818, 10.1002/ana.410410620
Balslev, 2000, Provocation of non-convulsive status epilepticus by tiagabine in three adolescent patients, Eur J Paediatr Neurol, 4, 169, 10.1053/ejpn.2000.0293
Baruzzi, 1994, Oxcarbazepine: pharmacokinetic interactions and their clinical relevance, Epilepsia, 35, 14, 10.1111/j.1528-1157.1994.tb05939.x
Baumgartner, C. H., Stefan, H. (2006). Epilepsien in Aktuelle Therapie in der Neurologie-Kompendium für die Fort-und Weiterbildung, Hrsg. Stefan, H., Mamoli, B., ECOMED Verlag, Landshut, 7. Ergänzungslieferung.
Benes, 1999, Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives, J Med Chem, 4, 2582, 10.1021/jm980627g
Ben-Menachem, 2000, Efficacy and tolerability of levetiracetam 3000 mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group, Epilepsia, 41, 1276, 10.1111/j.1528-1157.2000.tb04605.x
Betts, 2000, A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy, Seizure, 9, 80, 10.1053/seiz.2000.0380
Bill, 1997, A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy, Epilepsy Res, 27, 195, 10.1016/S0920-1211(97)00024-7
Birnstiel, 1997, Levetiracetam (ucb LO59) affects in vitro models of epilepsy in CA3 pyramidal neurons without altering normal synaptic transmission, Naunyn Schmiedebergs Arch Pharmacol, 356, 611, 10.1007/PL00005097
Biton, 1999, A randopmized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures. Topiramate YTC Study Group, Neurology, 53, 1162
Blackburn-Munro, 2005, Retigabine: chemical synthesis to clinical application, CNS Drug Rev, 11, 1, 10.1111/j.1527-3458.2005.tb00033.x
Blum, 1998, New drugs for persons with epilepsy, Adv Neurol, 76, 57
Blum, 1994, Pharmacokinetics of gabapentin in subjects with various degrees of renal function, Clin Pharmacol Ther, 56, 154, 10.1038/clpt.1994.118
Borowicz, 2004, Influence of the combined treatment of LY 300164 (an AMPA/kainate receptor antagonist) with adenosine receptor agonists on the electroconvulsive threshold in mice, Eur Neuropsychopharmacol, 14, 407, 10.1016/j.euroneuro.2003.12.003
Brodie, 1999, Multicenter, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy, Epilepsy Res, 37, 18, 10.1016/S0920-1211(99)00039-X
Brodie, 2002, Gabapentin Monotherapie versus Lamotrigin-Monotherapie: ein doppelblinder Vergleich bei neu diagnostizierter Epilepsie, Epilepsia, 43, 993, 10.1046/j.1528-1157.2002.45401.x
Brodie, 2005, Dosisabhängige Sicherheit und Wirksamkeit von zonisamid: Eine randomisierte, doppelblinde, plazebokontrollierte Studie an Patienten mit refraktären fokalen Anfällen, Epilepsia, 46, 31, 10.1111/j.1528-1167.2005.00355.x
Calbrese, 2000, A double-blind, placebo-controlled, prophylaxis study of lamotrigine in rapid-cycling bipolar disorder, J Clin Psychiatry, 61, 841, 10.4088/JCP.v61n1106
Cereghino, 2000, Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial, Neurology, 55, 236, 10.1212/WNL.55.2.236
Chadwick, 1996, Gabapentin in generalized seizures, Epilepsy Res, 25, 191, 10.1016/S0920-1211(96)00020-4
Cramer, 1999, New antiepileptic drugs: comparison of key trials, Epilepsia, 40, 590, 10.1111/j.1528-1157.1999.tb05561.x
Cramer, 2000, Effect of levetiracetam on epilepsy-related quality of life. N132 Study Group, Epilepsia, 41, 868, 10.1111/j.1528-1157.2000.tb00255.x
Cramer, 2001, Review of treatment options for refractory epilepsy: new medications and vagal nerve stimulation, Epilepsy Res, 47, 17, 10.1016/S0920-1211(01)00286-8
Crumrine, 1997, Lamotrigine protects hippocampal CA1 neurons from ischemic damage after cardiac arrest, Stroke, 28, 2230, 10.1161/01.STR.28.11.2230
Cunha, 2002, Effects of carbamazepine and novel 10,11-dihydro-5H-dibenz[b,f]azepine-5-carboxamide derivatives on synaptic transmission in rat hippocampal slices, Pharmacol Toxicol, 90, 208, 10.1034/j.1600-0773.2002.900407.x
Dam, 1989, A double-blind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy, Epilepsy Res, 3, 70, 10.1016/0920-1211(89)90070-3
Doheny, 1999, Blood and cerebrospinal fluid pharmacokinetics of the novel anticonvulsant levetiracetam (ucb L059) in the rat, Epilepsy Res, 34, 161, 10.1016/S0920-1211(98)00104-1
Edwards, 2001, Lamotrigine monotherapy improves depressive symptoms in epilepsy: a double-blind comparison with valproate, Epilepsy Behav, 2, 28, 10.1006/ebeh.2000.0143
Errante, 2003, Acute effects of gabapentin and pregabalin on rat forebrain cellular GABA, glutamate, and glutamine concentrations, Seizure, 12, 300, 10.1016/S1059-1311(02)00295-9
Errington, 2005, Voltage gated ion channels: targets for anticonvulsant drugs, Curr Top Med Chem, 5, 15, 10.2174/1568026053386872
Faught, 2001, Randomized controlled trial of zonisamide for the treatment of refractory partial onset seizures, Neurology, 7, 1777
Freiman, 2001, Modulation of K+-evoked [3H]-noradrenaline release from rat and human brain slices by gabapentin: involvement of KATP channels, Naunyn Schmiedebergs Arch Pharmacol, 363, 537, 10.1007/s002100100408
French, 2003, Pregabalin adjunctive therapy in patients with partial seizures, Neurology, 60, 1631, 10.1212/01.WNL.0000068024.20285.65
French, 2004, Efficacy and tolerability of the new antiepileptic drugs, I: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society, Epilepsia, 45, 401, 10.1111/j.0013-9580.2004.06204.x
French, 2004, Efficacy and tolerability of the new antiepileptic drugs, II: treatment of new-onset epilepsy: report of the TTA and QSS subcommittees of the American Academy of Neurology and the American Epilepsy Society, Epilepsia, 45, 410, 10.1111/j.0013-9580.2004.06304.x
Gatti, 2000, The new antiepileptic drugs: pharmacological and clinical aspects, Curr Pharm Des, 6, 839, 10.2174/1381612003400245
Genton, 2000, When antiepileptic drugs aggravate epilepsy, Brain Dev, 22, 75, 10.1016/S0387-7604(99)00113-8
Gidal, 1995, Weight gain and gabapentin therapy [letter], Ann Pharmacother, 29, 1048, 10.1177/106002809502901019
Gidal, 1996, Effect of a high-protein meal on gabapentin pharmacokinetics, Epilepsy Res, 23, 71, 10.1016/0920-1211(95)00051-8
Gironell, 1999, A randomized placebo-controlled comparative trial of gabapentin and propranolol in essential tremor, Arch Neurol, 56, 475, 10.1001/archneur.56.4.475
Goldlust, 1995, Effects of anticonvulsivant drug gabapentin on the enzymes in metabolic pathways of glutamate and GABA, Epilepsy Res, 22, 1, 10.1016/0920-1211(95)00028-9
Grant, 2000, Efficacy and tolerability of 1000–4000 mg per day of levetiracetam as add-on therapy in patients with refractory epilepsy, Epilepsy Res, 42, 89, 10.1016/S0920-1211(00)00158-3
Gryder, 2003, Selective antagonism of GluR5 kainate-receptor-mediated synaptic currents by topiramate in rat basolateral amygdala neurons, J Neurosci, 23, 7069, 10.1523/JNEUROSCI.23-18-07069.2003
Gustavson, 1998, Lack of a clinically significant pharmacokinetic drug interaction between tiagabine and valproate, Am J Ther, 5, 73, 10.1097/00045391-199803000-00004
Hammondet, 1987, Neuropharmacology of zonisamide, a new antiepileptic drug, Gen Pharmacol, 18, 303, 10.1016/0306-3623(87)90016-4
Hanaya, 1998, Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro, Brain Res, 780, 274, 10.1016/S0006-8993(98)00116-4
Herzog, 2003, Differential antiepileptic drug effects on sex hormones and reproductive hormones: a comparison between lamotrigne and enzyme-inducing antiepileptic drugs, Epilepsia, 44, 107
Hofmann, 1999, Voltage depedent calcium channels: from structure to function, Rev Physiol Biochem Pharmacol, 139, 33, 10.1007/BFb0033648
Holden, 1999, The effect of tiagabine on spasticity in children with intractable epilepsy: a pilot study, Pediatr Neurol, 21, 728, 10.1016/S0887-8994(99)00081-8
Honmou, 1995, Gabapentin potentiates the conductance increase induced by nipecotic acid in CA1 pyramidal neurons in vitro, Epilepsy Res, 20, 193, 10.1016/0920-1211(94)00076-9
Honmou, 1995, The anticonvulsant gabapentin enhances promoted release of GABA in hippocampus: a field potential analysis, Brain Res, 692, 273, 10.1016/0006-8993(95)00634-3
Hovinga, 2002, Novel anticonvulsant medications in development, Expert Opin Investig Drugs, 110, 1387, 10.1517/13543784.11.10.1387
Hovinga, 2003, SPM-927 (Schwarz Pharma), IDrugs, 6, 479
Isojaervi, 1995, Serum sex hormone levels after replacing carbamazepine with oxcarbazepine, Eur J Clin Pharmacol, 47, 462
Johannessen, 1987, Hyponatremia induced by oxcarbazepine, Epilepsy Res, 1, 155, 10.1016/0920-1211(87)90025-8
Kilpatrick, 1996, Concentration-effect and concentration-toxicity relations with lamotrigine: a prospective study, Epilepsia, 37, 534, 10.1111/j.1528-1157.1996.tb00605.x
Kiura, 2003, Involvement of Ca(2+) channels in abnormal excitability of hippocampal CA3 pyramidal cells in noda epileptic rats, J Pharmacol Sci, 91, 137, 10.1254/jphs.91.137
Klitgaard, 2005, Antiepileptic drug discovery: lessons from the past and future challenges, Acta Neurol Scand Suppl, 181, 68, 10.1111/j.1600-0404.2005.00513.x
Klosterskov, 1992, Possible interaction between oxcarbazepine and an oral contraceptive, Epilepsia, 33, 1149, 10.1111/j.1528-1157.1992.tb01773.x
Klugbauer, 2003, Clacium channel alpha2delta subunits:differntial expression, function, and drug binding, J Bioenerg Biomembr, 35, 639, 10.1023/B:JOBB.0000008028.41056.58
Kocsis, 1994, Gabapentin increases GABA-induced depolarization in rat neonatal optic nerve, Neurosci Lett, 169, 181, 10.1016/0304-3940(94)90386-7
Komatsu, 1995, Free radical scavenging activity of zonisamide and its inhibitory effect on lipid peroxide formation in iron-induced epileptogenic foci of rats, Neurosciences, 21, 23
Kothare, 2000, Gabapentin treatment in a child with delayed-onset hemichorea/hemiballismus, Pediatr Neurol, 22, 68, 10.1016/S0887-8994(99)00104-6
Kramer, 1992, Oxcarbazepine does not affect the anticoagulant activity of warfarin, Epilepsia, 33, 1145, 10.1111/j.1528-1157.1992.tb01772.x
Labiner, 2002, DP-VPA D-Pharm, Curr Opin Investig Drugs, 3, 921
Laird, 2000, Use of gabapentin in the treatment of neuropathic pain, Ann Pharmacother, 34, 802, 10.1345/aph.19303
Lamotrigine pregnanacy registry, January 2006, GlaxoSmithKline.
Larkin, 1991, Lack of enzyme induction with oxcarbazepine (600 mg daily) in healthy subjects, Br J Clin Pharmacol, 31, 65, 10.1111/j.1365-2125.1991.tb03858.x
Lieth, 2001, Nitrogen shuttling between neurons and glial cells during glutamate synthesis, J Neurochem, 76, 1712, 10.1046/j.1471-4159.2001.00156.x
Lingamaneni, 1999, Effects of anticonvulsants on veratridine and KCL-evoked gluitamate release from rat cortical synaptosomes, Neurosciences, 276, 127, 10.1016/S0304-3940(99)00810-1
Loffe, 2002, Reverse phase HPLC for polar lipids. Simple and selective HPLC procedures for analysis of phospholipid-based derivatives of valproic acid and various non-steroidal anti-inflammatory drugs, J Pharm Biomed Anal, 30, 391, 10.1016/S0731-7085(02)00220-0
Lofton, 2005, Evaluation of toxicity of topiramate exposures reported to poison centers, Hum Exp Toxicol, 24, 591, 10.1191/0960327105ht561oa
Loiseau, 1999, Review of controlled trials of gabitril (tiagabine): a clinician's viewpoint, Epilepsia, 40, 14, 10.1111/j.1528-1157.1999.tb02089.x
Löscher, 2000, Piracetam and levetiracetam, two pyrrolidone derivatives, exert antidystonic activity in a hamster model of paroxysmal dystonia, Eur J Pharmacol, 391, 251, 10.1016/S0014-2999(00)00105-9
Löscher, 2004, New horizons in the development of antiepileptic drugs II: the search for new targets, Epilepsy Res, 60, 77
Lynch, 2004, The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam, PAS, 26, 9861, 10.1073/pnas.0308208101
MacDonald, 2002
MacDonald, R.L., Meldrum, B.S., (1995). Principles of antiepileptic drug action in antiepileptic drugs for sedition edited by R.H. Levy, R.H. Mattson and B.S. Meldrum, Raven Press Ltd. New York p 61-77 and M.A. Rogawsky. Principals of antiepileptic drug action in antiepileptic drugs. Eds. Rene H. Levy, Richard Mattson, B.S. Meldrum, Emilio Perucca, p. 8.
Malawska, 2005, Brivaracetam UCB, Curr Opin Investig Drugs, 6, 740
Malek, 2003, Remacemide — a novel potential antiepileptic drug, Pol J Pharmacol, 5, 691
Marais, 2001, Calcium channel α2δ subunits: structure and gabapentin binding, Mol Pharmacol, 59, 1243, 10.1124/mol.59.5.1243
Margineanu, 2001, Can gap-junction blockade preferentially inhibit neuronal hypersynchron excitability?, Neuropharmacology, 41, 377, 10.1016/S0028-3908(01)00080-6
Martin, 1999, Cognitive effects of topiramate, gabapentine and lamotrigine in healthy young adults, Neurology, 52, 321, 10.1212/WNL.52.2.321
Marzo, 2004, Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity, Pharmacol Res, 50, 77, 10.1016/j.phrs.2003.12.004
Masson, 1999, Neurotransmitter transporters in the central nervous system, Coll Rev, 51, 439
Matsumoto, 1964, Cortical cellelular phenomena in experimental epilepsy: interictal manifestation, Exp Neurol, 9, 286, 10.1016/0014-4886(64)90025-1
Mazarati, 2002, Anticonvulsant and antiepileptogenic effects of fluorofelbamate in experimental status epilepticus, Seizure, 7, 423, 10.1053/seiz.2002.0677
McKee, 1994, A double-blind, placebo-controlled interaction study between oxcarbazepine and carbamazepine, blind sodium valproate and phenytoin in epileptic patients, Br J Clin Pharmacol, 37, 27, 10.1111/j.1365-2125.1994.tb04234.x
McLean, 1999, Gabapentin in the management of convulsive disorders, Epilepsia, 40, 39, 10.1111/j.1528-1157.1999.tb00932.x
Meador, 2001, Differential cognitive and behavioral effects of carbamazepine and lamotrigine, Neurology, 56, 177, 10.1212/WNL.56.9.1177
Meldrum, 1999, Basic mechanisms of gabitril (tiagabine) and future potential developments, Epilepsia, 40, 2, 10.1111/j.1528-1157.1999.tb02087.x
Messenheimer, 2000, Rash with lamotrigine: dosing guidelines [letter], Epilepsia, 41, 488, 10.1111/j.1528-1157.2000.tb00197.x
Miles, 1998, Single neurons can initiate synchronized population discharge in the hippocampus, Nature, 306, 371, 10.1038/306371a0
Miles, 2004, Feasibility and limitations of oxcarbazepine monitoring using salivary monohydroxycarbazepine (MHD), Ther Drug Monit, 26, 300, 10.1097/00007691-200406000-00014
Nicolas, 1999, In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent, Drug Metab Dispos, 27, 250
Okada, 1999, Biphasic effects of zonisamide on serotonergic system in rat hippocampus, Epilepsy Res, 34, 187, 10.1016/S0920-1211(98)00109-0
Pack, 2003, Bone mineral density in an outpatient population receiving enzyme-inducing antiepileptic drugs, Epilepsy Behav, 4, 169, 10.1016/S1525-5050(03)00036-2
Parker, 2005, Stability and comparative metabolism of selected felbamate metabolites and postulated fluorofelbamate metabolites by Postmitochondrial suspensions, Chem Res Toxicol, 18, 1842, 10.1021/tx050130r
Parri, 1998, Sodium current in rat and cat salamo cortical neurons: role of non-inactivating component in tonic and burst firing, J Neurosci, 18, 854, 10.1523/JNEUROSCI.18-03-00854.1998
Patsalos, 2000, Pharmacokinetic profile of Levetiracetam: Toward ideal characteristics, Pharmacol Ther, 85, 77, 10.1016/S0163-7258(99)00052-2
Perucca, 1996, Pharmacokinetic profile of topiramate in comparison with other new antiepileptic drugs, Epilepsia, 37, 8, 10.1111/j.1528-1157.1996.tb06032.x
Perucca, 2004, 913
Petroff, 1996, The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy, Ann Neurol, 39, 95, 10.1002/ana.410390114
Philippi, 1995, Serotonin- and proton-induced and modified ionic currents in frog sensory neurons, J Neurosci Res, 40, 387, 10.1002/jnr.490400313
Pisani, 1999, The efficacy of valproate-lamotrigine comedication in refractory complex partial seizures: evidence for a pharmacodynamic interaction, Epilepsia, 40, 1141, 10.1111/j.1528-1157.1999.tb00832.x
Pisani, 2004, Intracellular calcium increase in epileptiform acticity: modulation by levetiracetam and lamotrigine, Epilepsia, 45, 719, 10.1111/j.0013-9580.2004.02204.x
Poisson, 1984, A new type of anticonvulsant, stiripentol. Pharmacological profile and neurochemical study, Arzneimittelforschung, 34, 199
Poolos, 2002, Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites, Nat Neurosci, 5, 767, 10.1038/nn891
Poulain, 2002, Levetiracetam opposes the action of GABAA antagonists in hypothalamic neurones, Neuropharmacology, 42, 346, 10.1016/S0028-3908(01)00185-X
Poulsen, 2004, Modulation by topiramate of AMPA and kainate mediated calcium influx in cultured cerebral cortical, hippocampal and cerebellar neurons, Neurochem Res, 29, 275, 10.1023/B:NERE.0000010456.92887.3b
Ragstale, 1998, Soldium as molecular targets for antiepileptic drugs, Brain Res Rev, 26, 16, 10.1016/S0165-0173(97)00054-4
Ramael, 2006, Levetricaetam intravenous infusion: A randomized, placebo-controlled safety and pharmacokinetic study, Epilepsia, 47, 1128, 10.1111/j.1528-1167.2006.00586.x
Rambeck, 1993, Lamotrigine clinical pharmacokinetics, Clin Pharmacokinet, 25, 433, 10.2165/00003088-199325060-00003
Rambeck, 1997, Concentrations of lamotrigine in a mother on lamotrigine treatment and her newborn child, Eur J Clin Pharmacol, 51, 481, 10.1007/s002280050234
Ramsay, 2000, Epilepsy in the elderly, Neurology, 55, 9
Rao, 1988, Gabapentin augments whole blood serotonin in healthy young men, J Neural Transm, 73, 129, 10.1007/BF01243384
Reddy, 2004, Role of neurosteroids in catamenial epilepsy, Epilepsy Res, 62, 99, 10.1016/j.eplepsyres.2004.09.003
Reeves, 1996, Movement disorders associated with the use of gabapentin, Epilepsia, 37, 988, 10.1111/j.1528-1157.1996.tb00537.x
Reife, 2000, Topiramate as add-on therapy: pooled analysis of randomized controlled trials in adults, Epilepsia, 41, 66, 10.1111/j.1528-1157.2000.tb02175.x
Rigo, 2002, The anti-epileptic drug levetriacetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents, Br J Pharmacol, 136, 659, 10.1038/sj.bjp.0704766
Ritter, 2000, Effectiveness, tolerability, and safety of topiramate in children with partial-onset seizures. Topiramate YP Study Group, Epilepsia, 41, 82, 10.1111/j.1528-1157.2000.tb02178.x
Rogawski, 2002, Principles of antiepileptic drug action, 1
Rosenfeld, 1997, Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy, Epilepsia, 38, 317, 10.1111/j.1528-1157.1997.tb01123.x
Rutecki, 1995, Noradrenergic modulation of epileptiform activity in the hippocampus, Epilepsy Res, 20, 125, 10.1016/0920-1211(94)00078-B
Sachdeo, 1997, Topiramate monotherapy for partial onset seizures [see comments], Epilepsia, 38, 294, 10.1111/j.1528-1157.1997.tb01120.x
Sackellares, 1997, Controlled clinical trial of zonisamide: an effective adjunctive treatment for refractory partial seizures
Sadler, 1999, Lamotrigine associated with insomnia, Epilepsia, 40, 322, 10.1111/j.1528-1157.1999.tb00712.x
Sander, 1997, Practical aspects of the use of topiramate in patients with epilepsy, Epilepsia, 38, 56, 10.1111/j.1528-1157.1997.tb04521.x
Schachter, 1999, Oxcarbazepine: double-blind, randomized, placebo-control, monotherapy trial for partial seizures [see comments], Neurology, 52, 732, 10.1212/WNL.52.4.732
Schachter, 1999, Oxcarbazepine in a monotherapy trial for partial seizures-placebo-controlled studies in neurology: where do they stop?, Neurology, 53, 2211, 10.1212/WNL.53.9.2211
Schapel, 1993, Double-blind placebo-controlled, cross-over study of lamotrigine in treatment resistant partial seizure, J Neurosurg Psychiatry, 56, 448, 10.1136/jnnp.56.5.448
Schauf, 1987, Zonisamide enhances slow sodium inactivation in Myxicola, Brain Res, 413, 185, 10.1016/0006-8993(87)90168-5
Schmidt, 1993, Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial, Epilepsy Res, 15, 67, 10.1016/0920-1211(93)90011-U
Schwartzkroin, 1978, Cellular and field potential properties of epileptogenic hippocampous slices, Brain Res, 147, 117, 10.1016/0006-8993(78)90776-X
Schwartzkroin, 1980, Effects of EGTA on the calcium activated after hyperpolarisation in hippocamapl CA3 pyramidal cells, Science, 210, 1125, 10.1126/science.6777871
Shah, 2002
Sharief, 1996, Double-blind, placebo-controlled study of topiramate in patients with refractory partial epilepsy, Epilepsy Res, 25, 217, 10.1016/S0920-1211(96)00029-0
Shorvon, 2000, Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. European Levetiracetam Study Group, Epilepsia, 41, 1179, 10.1111/j.1528-1157.2000.tb00323.x
Shuaib, 1995, Neuroprotective effects of lamotrigine in global ischemia in gerbils. A histological, in vivo microdialysis and behavioral study, Brain Res, 702, 199, 10.1016/0006-8993(95)01048-1
Sills, 1997, Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain, Eur J Pharmacol, 325, 35, 10.1016/S0014-2999(97)00105-2
Silverman, 1991, 3-Alkyl-4-aminobutyric acids: the first class of anticonvulsant agents that activates L-glutamic acid decarboxylase, J Med Chem, 34, 2295, 10.1021/jm00111a053
Stefan, 1998, The challenge: epilepsy treatment, 1
Stefan, 1999
Stefan, 2006, Onset otf action of levetiracetam: a RCT trial using therapeutic intensive seizure analysis (TISA), Epilepsia, 47, 1, 10.1111/j.1528-1167.2006.00461.x
Stefan, 2006, Epileptogenesis and rational therapeutic strategies, Acta Neurol Scand, 113, 139, 10.1111/j.1600-0404.2005.00561.x
Stefani, 1995, Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system: II. Modulation of high-voltage-activated calcium currents, Epilepsia, 36, 997, 10.1111/j.1528-1157.1995.tb00958.x
Stefani, 1997, Differential inhibition by riluzole, lamotrigine and phenytoin of sodium and calcium currents in cortical neurons: implications for neuroprotective strategies, Exp Neurol, 147, 115, 10.1006/exnr.1997.6554
Stefani, 1998, Gabapentin inhibits calcium currents in isolated rat brain neurons, Neuropharmacology, 37, 83, 10.1016/S0028-3908(97)00189-5
Stefani, 1998, The lamotrigine analogue 619 C 89 has been shown to inhibit sodium channels and cloned N typed calcium channels, Br J Pharmacol, 125, 1058, 10.1038/sj.bjp.0702134
Steiner, 1999, Lamotrigine monotherapy in newly diagnosed untreated epilepsy: double-blind comparison with Phenytoin, Epilepsia, 40, 601, 10.1111/j.1528-1157.1999.tb05562.x
Steinhoff, 2003, The ideal characteristics of antiepileptic therapy: an overview of old and new AEDs, Acta Neurol Scand, 107, 87, 10.1034/j.1600-0404.2003.01311.x
Surges, 2003, Gabapentin increases the hyperpolarization-activated cation current Ih in rat CA1 pyramidal cells, Epilepsia, 44, 150, 10.1046/j.1528-1157.2003.36802.x
Taylor, 1998, Summary of mechanistic hypotheses of gabapentin pharmacology, Epilepsy Res, 29, 233, 10.1016/S0920-1211(97)00084-3
Trimble, 2000, Psychiatric symptoms after therapy with new antiepileptic drugs: psychopathological and seizure related variables, Seizure, 9, 249, 10.1053/seiz.2000.0405
Trojnar, 2005, A novel antiepileptic drug, Pharmacol Reprod, 57, 154
Turner, 1998, Calcium channels coupled to glutamate release, Prog Brain Res, 116, 3, 10.1016/S0079-6123(08)60426-4
Uvebrant, 1994, Intractable epilepsy in children: the efficacy of lamotrigin treatment including non-seizure related benefit, Neuropediatrics, 25, 284, 10.1055/s-2008-1073041
Verma, 1999, Lamotrigine-induced blepharospasm, Pharmacotherapy, 19, 877, 10.1592/phco.19.10.877.31554
Wamil, 1994, Limitation by gabapentin of high frequency action potential firing by mouse central neurons in cell culture, Epilepsy Res, 17, 1, 10.1016/0920-1211(94)90074-4
Wang, 1996, Presynaptic inhibition of excitatory neurotransmission by lamotrigine in the rat amygdalar neurons, Synapse, 24, 248, 10.1002/(SICI)1098-2396(199611)24:3<248::AID-SYN7>3.0.CO;2-E
Wang, 2003, A kindling model of pharmacoresistant temporal lobe epilepsy in sprague-dawley rats induced by coriaria lactone and its possible mechanism, Epilepsia, 44, 475, 10.1046/j.1528-1157.2003.32502.x
Wegmann, 1997, Pharmaco-cellular enzymology of the mode of action of Stiripentol during cardiazolic epilepsia: IV. Cellular and tissular repartition of 3H-Stiripentol, Cell Mol Biol Incl Cyto Enzymol, 24, 51
White, 2000, Topiramate modulates GABA evoked currents in murine cortical neurons by a non-benzodiazepine mechnism, Epilepsia, 41, 17, 10.1111/j.1528-1157.2000.tb02165.x
Wickenden, 2002, Potassium channels as anti-epileptic drug targets, Neuropharmacology, 43, 1055, 10.1016/S0028-3908(02)00237-X
Wong, 1979, Dendritic mechanisms underlying penicillininduced epileptiform activity, Science, 204, 1228, 10.1126/science.451569
Yagi, 1992, Open clinical trial of new antiepileptic drug, zonisaminde (ZNA) on 49 patients with refractory epileptic seizure, Clin Psychiatry, 29, 111
Yan, 1992, Evidence that carbamazepine and antiepilepsirine may produce a component of their anticonvulsant effects by activating serotonergic neurons in genetically epilepsy-prone rats, J Pharmacol Exp Ther, 261, 652
Yoshida, 2005, Effects of zonisamide on neurotransmitter exocytosis associated with ryanodine receptors, Epilepsy Res, 67, 153, 10.1016/j.eplepsyres.2005.10.001
Zaccara, 1993, Influence of single and repeated doses of oxcarbazepine on the pharmacokinetic profile of felodipine, Ther Drug Monit, 15, 39, 10.1097/00007691-199302000-00007
Zipp, 1993, Lamotrigine-antiparkinsonian activity by blockade of glutamate release?, J Neural Transm Parkinsons Dis Dement Sect, 5, 67, 10.1007/BF02260916